| Cynthia G Smith, LCSW | |
|
261 Highway 132, Mangham, LA 71259-5269 | |
| (318) 248-2807 | |
| (318) 812-6603 |
| Full Name | Cynthia G Smith |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | 261 Highway 132, Mangham, Louisiana |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053046631 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 6931 (Louisiana) | Primary |
| Entity Name | Monroe Surgical Hospital, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225031495 PECOS PAC ID: 5294725297 Enrollment ID: O20040513000085 |
News Archive
Neurologix, Inc., today announced positive results in a Phase 2 trial of its investigational gene therapy for advanced Parkinson's disease, NLX-P101. Study participants who received NLX-P101 experienced statistically significant and clinically meaningful improvements in off-medication motor scores compared to control subjects who received sham surgery.
A study released today at the Society of Gynecologic Oncologists 38th Annual Meeting on Women's Cancer found few patients were aware of genetic cancer syndromes and the high risk of developing cancer if genetic mutations were found. Fewer still were motivated to follow up on this information with their own healthcare provider or genetic counseling/testing services.
European experts in cardiovascular medicine will today gather at a two day symposium to address the national agenda on cardiovascular disease prevention, held at Imperial College London and sponsored by leading independent academic and professional publisher SAGE.
A cross-sectional online survey conducted by the scientists of Johns Hopkins Bloomberg School of Public Health, USA, has revealed that about 41% of US residents are unwilling to receive a coronavirus disease 2019 (COVID-19) vaccine due to concern over vaccine safety and efficacy. Moreover, there are sub-group variations in willingness to receive a COVID-19 vaccine
Below is a statement released today by Laphonza Butler, President of SEIU ULTCW, in response to Governor Schwarzenegger's May Revise and his proposed $750 million in cuts to In-Home Supportive Services:
› Verified 3 days ago
| Entity Name | Affinity Health Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023291226 PECOS PAC ID: 9335226547 Enrollment ID: O20080411000088 |
News Archive
Neurologix, Inc., today announced positive results in a Phase 2 trial of its investigational gene therapy for advanced Parkinson's disease, NLX-P101. Study participants who received NLX-P101 experienced statistically significant and clinically meaningful improvements in off-medication motor scores compared to control subjects who received sham surgery.
A study released today at the Society of Gynecologic Oncologists 38th Annual Meeting on Women's Cancer found few patients were aware of genetic cancer syndromes and the high risk of developing cancer if genetic mutations were found. Fewer still were motivated to follow up on this information with their own healthcare provider or genetic counseling/testing services.
European experts in cardiovascular medicine will today gather at a two day symposium to address the national agenda on cardiovascular disease prevention, held at Imperial College London and sponsored by leading independent academic and professional publisher SAGE.
A cross-sectional online survey conducted by the scientists of Johns Hopkins Bloomberg School of Public Health, USA, has revealed that about 41% of US residents are unwilling to receive a coronavirus disease 2019 (COVID-19) vaccine due to concern over vaccine safety and efficacy. Moreover, there are sub-group variations in willingness to receive a COVID-19 vaccine
Below is a statement released today by Laphonza Butler, President of SEIU ULTCW, in response to Governor Schwarzenegger's May Revise and his proposed $750 million in cuts to In-Home Supportive Services:
› Verified 3 days ago
| Entity Name | Thinktrek Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215415229 PECOS PAC ID: 1951754951 Enrollment ID: O20240125003776 |
News Archive
Neurologix, Inc., today announced positive results in a Phase 2 trial of its investigational gene therapy for advanced Parkinson's disease, NLX-P101. Study participants who received NLX-P101 experienced statistically significant and clinically meaningful improvements in off-medication motor scores compared to control subjects who received sham surgery.
A study released today at the Society of Gynecologic Oncologists 38th Annual Meeting on Women's Cancer found few patients were aware of genetic cancer syndromes and the high risk of developing cancer if genetic mutations were found. Fewer still were motivated to follow up on this information with their own healthcare provider or genetic counseling/testing services.
European experts in cardiovascular medicine will today gather at a two day symposium to address the national agenda on cardiovascular disease prevention, held at Imperial College London and sponsored by leading independent academic and professional publisher SAGE.
A cross-sectional online survey conducted by the scientists of Johns Hopkins Bloomberg School of Public Health, USA, has revealed that about 41% of US residents are unwilling to receive a coronavirus disease 2019 (COVID-19) vaccine due to concern over vaccine safety and efficacy. Moreover, there are sub-group variations in willingness to receive a COVID-19 vaccine
Below is a statement released today by Laphonza Butler, President of SEIU ULTCW, in response to Governor Schwarzenegger's May Revise and his proposed $750 million in cuts to In-Home Supportive Services:
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Cynthia G Smith, LCSW Po Box 51193, Lafayette, LA 70505-1193 Ph: (318) 807-7875 | Cynthia G Smith, LCSW 261 Highway 132, Mangham, LA 71259-5269 Ph: (318) 248-2807 |
News Archive
Neurologix, Inc., today announced positive results in a Phase 2 trial of its investigational gene therapy for advanced Parkinson's disease, NLX-P101. Study participants who received NLX-P101 experienced statistically significant and clinically meaningful improvements in off-medication motor scores compared to control subjects who received sham surgery.
A study released today at the Society of Gynecologic Oncologists 38th Annual Meeting on Women's Cancer found few patients were aware of genetic cancer syndromes and the high risk of developing cancer if genetic mutations were found. Fewer still were motivated to follow up on this information with their own healthcare provider or genetic counseling/testing services.
European experts in cardiovascular medicine will today gather at a two day symposium to address the national agenda on cardiovascular disease prevention, held at Imperial College London and sponsored by leading independent academic and professional publisher SAGE.
A cross-sectional online survey conducted by the scientists of Johns Hopkins Bloomberg School of Public Health, USA, has revealed that about 41% of US residents are unwilling to receive a coronavirus disease 2019 (COVID-19) vaccine due to concern over vaccine safety and efficacy. Moreover, there are sub-group variations in willingness to receive a COVID-19 vaccine
Below is a statement released today by Laphonza Butler, President of SEIU ULTCW, in response to Governor Schwarzenegger's May Revise and his proposed $750 million in cuts to In-Home Supportive Services:
› Verified 3 days ago
Mr. Christopher Blake Leblanc, LCSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 261 Highway 132, Mangham, LA 71259 Phone: 318-248-2807 Fax: 318-248-2967 |